PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability.
Adenocarcinoma
/ etiology
Adult
Aged
B7-H1 Antigen
/ metabolism
Biomarkers, Tumor
/ analysis
Celiac Disease
/ complications
Crohn Disease
/ complications
Female
Humans
Intestinal Neoplasms
/ etiology
Intestine, Small
/ pathology
Lymphocytes, Tumor-Infiltrating
/ pathology
Male
Microsatellite Instability
Middle Aged
Retrospective Studies
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
20
11
2019
accepted:
27
01
2020
revised:
25
01
2020
pubmed:
19
2
2020
medline:
9
7
2021
entrez:
19
2
2020
Statut:
ppublish
Résumé
Small bowel adenocarcinomas (SBAs) are often associated with poor prognosis and have limited therapeutic options. Programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway blockade is an effective treatment in many microsatellite instability-high (MSI-H) solid tumors. We aimed at investigating PD-L1 and PD-1 expression in non-hereditary, non-ampullary SBAs, associated with celiac disease (CeD), Crohn's disease (CrD), or sporadic, recruited through the Small Bowel Cancer Italian Consortium. We assessed PD-L1 and PD-1 by immunohistochemistry in a series of 121 surgically resected SBAs, including 34 CeD-SBAs, 49 CrD-SBAs, and 38 sporadic SBAs. PD-L1 and PD-1 expression was correlated with several clinico-pathological features, such as the etiology, microsatellite instability status, and tumor-infiltrating lymphocyte (TIL) density. The prevalence of PD-L1 positivity according to combined positive score (CPS) was 26% in the whole cohort of SBAs, with significantly (p = 0.001) higher percentage (35%) in both CeD-SBAs and CrD-SBAs in comparison with sporadic SBAs (5%). CPS ≥ 1 SBAs were significantly (p = 0.013) more frequent in MSI-H cases (41%) than in non-MSI-H ones (18%); however, 15 CPS ≥ 1 microsatellite stable SBAs were also identified. CPS ≥ 1 SBAs showed higher TIL and PD-1
Identifiants
pubmed: 32066859
doi: 10.1038/s41379-020-0497-0
pii: S0893-3952(22)00823-7
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1398-1409Commentaires et corrections
Type : ErratumIn
Références
Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg. 2010;199:797–803.
doi: 10.1016/j.amjsurg.2009.05.037
Giuffrida P, Vanoli A, Arpa G, Bonometti A, Luinetti O, Solcia E, et al. Small bowel carcinomas associated with immune-mediated intestinal disorders: the current knowledge. Cancers (Basel) 2018;11:1.
doi: 10.3390/cancers11010031
Vanoli A, Di Sabatino A, Furlan D, Klersy C, Grillo F, Fiocca R, et al. Small bowel carcinomas in celiac or crohn’s disease: clinico-pathological, molecular, and prognostic features. a study from the small bowel cancer italian consortium. J Crohns Colitis. 2017;11:942–53.
doi: 10.1093/ecco-jcc/jjx031
Vanoli A, Di Sabatino A, Martino M, Klersy C, Grillo F, Mescoli C, et al. Small bowel carcinomas in celiac or Crohn’s disease: distinctive histophenotypic, molecular and histogenetic patterns. Mod Pathol 2017;30:1453–66.
doi: 10.1038/modpathol.2017.40
Diosdado B, Buffart TE, Watkins R, Carvalho B, Ylstra B, Tijssen M, et al. High-resolution array comparative genomic hybridization in sporadic and celiac disease-related small bowel adenocarcinomas. Clin Cancer Res. 2010;16:1391–401.
doi: 10.1158/1078-0432.CCR-09-1773
Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153–67.
doi: 10.1038/nri.2017.108
Chen C, Zhang F, Zhou N, Gu YM, Zhang YT, He YD, et al. Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Oncoimmunology 2019;8:e1581547.
doi: 10.1080/2162402X.2019.1581547
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.
doi: 10.1056/NEJMoa1500596
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409–13.
doi: 10.1126/science.aan6733
Thota R, Gonzalez RS, Berlin J, Cardin DB, Shi C. Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma? Am J Clin Pathol. 2017;148:208–14.
doi: 10.1093/AJCP/AQX070
Watari J, Mitani S, Ito C, Tozawa K, Tomita T, Oshima T, et al. Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. Sci Rep. 2019;9:10526.
doi: 10.1038/s41598-019-46167-y
Noh BJ, Hong SM, Jun SY, Eom DW. Prognostic implications of immune classification in a multicenter cohort of patients with small intestinal adenocarcinoma. Pathology 2020;52:228–35.
Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, et al. Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Mol Cancer Res. 2018;16:805–12.
doi: 10.1158/1541-7786.MCR-17-0735
Crumley S, Kurnit K, Hudgens C, Fellman B, Tetzlaff MT, Broaddus R. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Mod Pathol 2019;32:396–404.
doi: 10.1038/s41379-018-0148-x
Lee LH, Cavalcanti MS, Segal NH, Hechtman JF, Weiser MR, Smith JJ, et al. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod Pathol 2016;29:1433–42.
doi: 10.1038/modpathol.2016.139
Inaguma S, Lasota J, Wang Z, Felisiak-Golabek A, Ikeda H, Miettinen M. Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol 2017;30:278–85.
doi: 10.1038/modpathol.2016.185
De Rosa S, Sahnane N, Tibiletti MG, Magnoli F, Vanoli A, Sessa F, et al. EBV
Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 2018;31:214–34.
doi: 10.1038/modpathol.2017.156
Di Sabatino A, Corazza GR. Celiac disease. Lancet 2009;373:1480–93.
doi: 10.1016/S0140-6736(09)60254-3
Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.
doi: 10.1093/ecco-jcc/jjw168
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, Eds. AJCC cancer staging manual, 7th ed. New York, NY: Springer, 2010. p.127–32.
Chiaravalli AM, Feltri M, Bertolini V, Bagnoli E, Furlan D, Cerutti R, et al. Intratumor T cells, their activation status and survival in gastric carcinomas characterized for microsatellite instability and Epstein-Barr virus infection. Virchows Arch 2006;448:344–53.
doi: 10.1007/s00428-005-0066-4
Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143:330–7.
doi: 10.5858/arpa.2018-0043-OA
Wood SM, Gill AJ, Brodsky AS, Lu S, Friedman K, Karashchuk G, et al. Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway. Mod Pathol 2017;30:123–33.
doi: 10.1038/modpathol.2016.170
Vanoli A, Di Sabatino A, Martino M, Dallera E, Furlan D, Mescoli C, et al. Epstein-Barr virus-positive ileal carcinomas associated with Crohn’s disease. Virchows Arch 2017;471:549–52.
doi: 10.1007/s00428-017-2209-9
Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 2015;75:2139–45.
doi: 10.1158/0008-5472.CAN-15-0255
Arpa G, Grillo F, Giuffrida P, Nesi G, Klersy C, Mescoli C, et al. Separation of low versus high grade Crohn’s disease-associated small bowel carcinomas is improved by invasive front prognostic marker analysis. J Crohns Colitis. 2019. [Epub ahead of print].
Rizzo F, Vanoli A, Sahnane N, Cerutti R, Trapani D, Rinaldi A, et al. Small-bowel carcinomas associated with celiac disease: transcriptomic profiling shows predominance of microsatellite instability-immune and mesenchymal subtypes. Virchows Arch. 2019. [Epub ahead of print].
Pedersen K, Foster N, Overman M, Boland P, Kim S, Arrambide K, et al. ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA). Ann Oncol. 2019;30. https://doi.org/10.1093/annonc/mdz154.006 .
Ponce de León C, Angel López-Casado M, Lorite P, Palomeque T, Isabel Torres M. Dysregulation of the PD-1/PD-L1 pathway contributes to the pathogenesis of celiac disease. Cell Mol Immunol. 2019;16:777–9.
doi: 10.1038/s41423-019-0256-7
Ma F, Zhao M, Song Z, Wang Z. T-bet interferes with PD-1/PD-L1-mediated suppression of CD4(+) T cell inflammation and survival in Crohn’s disease. Clin Exp Pharm Physiol. 2019;46:798–805.
doi: 10.1111/1440-1681.13127
Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, Koganei K, et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol 2003;171:4156–63.
doi: 10.4049/jimmunol.171.8.4156
Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, et al. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist 2019;24:327–37.
doi: 10.1634/theoncologist.2018-0618
Giuffrida P, Corazza GR, Di Sabatino A. Old and new lymphocyte players in inflammatory bowel disease. Dig Dis Sci. 2018;63:277–88.
doi: 10.1007/s10620-017-4892-4
Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 2016;29:1104–12.
doi: 10.1038/modpathol.2016.95
Mantovani A, Romero P, Palucka AK, Marincola FM. Tumor immunity: effector response to tumor and role of the microenvironment. Lancet 2008;371:771–83.
doi: 10.1016/S0140-6736(08)60241-X
Von Rahden BH, Langner C, Brücher BL, Stein HJ, Sarbia M. No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection. Mol Carcinog 2006;45:349–52.
doi: 10.1002/mc.20163
Minamoto T, Mai M, Watanabe K, Ooi A, Kitamura T, Takahashi Y, et al. Medullary carcinoma with lymphocytic infiltration of the stomach. Clinicopathologic study of 27 cases and immunohistochemical analysis of the subpopulations of infiltrating lymphocytes in the tumor. Cancer. 1990;66:945–52.
doi: 10.1002/1097-0142(19900901)66:5<945::AID-CNCR2820660523>3.0.CO;2-X
Friedman K, Brodsky AS, Lu S, Wood S, Gill AJ, Lombardo K, et al. Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. Mod Pathol 2016;29:528–41.
doi: 10.1038/modpathol.2016.54
Brcic I, Cathomas G, Vanoli A, Jilek K, Giuffrida P, Langner C. Medullary carcinoma of the small bowel. Histopathology 2016;69:136–40.
doi: 10.1111/his.12908
Jun SY, Park ES, Lee JJ, Chang HK, Jung ES, Oh YH, et al. Prognostic significance of stromal and intraepithelial tumor-infiltrating lymphocytes in small intestinal adenocarcinoma. Am J Clin Pathol 2020;153:105–18.
doi: 10.1093/ajcp/aqz136